None of the observed changes were related to a specific COO in our DLBCL cell line panel, indicating that initial inhibitor sensitivity or CHOP-induced anti-apoptotic changes might not be related to the differentiation stadium at which DLBCL might occur. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.